| International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? T Shiroiwa, YK Sung, T Fukuda, HC Lang, SC Bae, K Tsutani Health economics 19 (4), 422-437, 2010 | 759 | 2010 |
| Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D T Shiroiwa, T Fukuda, S Ikeda, A Igarashi, S Noto, S Saito, K Shimozuma Quality of life research 25, 707-719, 2016 | 255 | 2016 |
| Comparison of value set based on DCE and/or TTO data: scoring for EQ-5D-5L health states in Japan T Shiroiwa, S Ikeda, S Noto, A Igarashi, T Fukuda, S Saito, K Shimozuma Value in Health 19 (5), 648-654, 2016 | 196 | 2016 |
| Developing a Japanese version of the EQ-5D-5L value set. S Ikeda, T Shiroiwa, A Igarashi, S Noto, T Fukuda, S Saito, K Shimozuma Journal of the National Institute of Public Health 64 (1), 47-55, 2015 | 166 | 2015 |
| Development of an official guideline for the economic evaluation of drugs/medical devices in Japan T Shiroiwa, T Fukuda, S Ikeda, T Takura, K Moriwaki Value in Health 20 (3), 372-378, 2017 | 138 | 2017 |
| WTP for a QALY and health states: More money for severer health states? T Shiroiwa, A Igarashi, T Fukuda, S Ikeda Cost Effectiveness and Resource Allocation 11, 1-7, 2013 | 123 | 2013 |
| Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery N Taira, K Shimozuma, T Shiroiwa, S Ohsumi, K Kuroi, S Saji, M Saito, ... Breast cancer research and treatment 128, 735-747, 2011 | 121 | 2011 |
| Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial T Shiroiwa, T Fukuda, K Shimozuma British journal of cancer 105 (9), 1273-1278, 2011 | 79 | 2011 |
| Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan T Shiroiwa, T Fukuda, K Tsutani Clinical therapeutics 29 (10), 2256-2267, 2007 | 64 | 2007 |
| Guideline for economic evaluation of healthcare technologies in Japan T FUKUDA, T SHIROIWA, SYA IKEDA, A IGARASHI, M AKAZAWA, ... 保健医療科学 62 (6), 325-640, 2013 | 61 | 2013 |
| Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system M Hasegawa, S Komoto, T Shiroiwa, T Fukuda Value in Health 23 (1), 43-51, 2020 | 60 | 2020 |
| The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data T Shiroiwa, T Fukuda, K Shimozuma, Y Ohashi, K Tsutani Breast cancer research and treatment 109, 559-566, 2008 | 60 | 2008 |
| Cost-Effectiveness Analysis of KRAS Testing and Cetuximab as Last-Line Therapy for Colorectal Cancer T Shiroiwa, Y Motoo, K Tsutani Molecular Diagnosis & Therapy 14, 375-384, 2010 | 56 | 2010 |
| New decision-making processes for the pricing of health technologies in Japan: the FY 2016/2017 pilot phase for the introduction of economic evaluations T Shiroiwa, T Fukuda, S Ikeda, T Takura Health Policy 121 (8), 836-841, 2017 | 54 | 2017 |
| Impact of preservation of the intercostobrachial nerve during axillary dissection on sensory change and health-related quality of life 2 years after breast cancer surgery N Taira, K Shimozuma, S Ohsumi, K Kuroi, T Shiroiwa, T Watanabe, ... Breast Cancer 21, 183-190, 2014 | 51 | 2014 |
| Valuation survey of EQ-5D-Y based on the international common protocol: development of a value set in Japan T Shiroiwa, S Ikeda, S Noto, T Fukuda, E Stolk Medical Decision Making 41 (5), 597-606, 2021 | 50 | 2021 |
| Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials T Shiroiwa, T Fukuda, K Tsutani British journal of cancer 101 (1), 12-18, 2009 | 50 | 2009 |
| Healthcare costs for the elderly in Japan: Analysis of medical care and long-term care claim records N Akiyama, T Shiroiwa, T Fukuda, S Murashima, K Hayashida PLoS One 13 (5), e0190392, 2018 | 44 | 2018 |
| Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer Y Narita, Y Matsushima, T Shiroiwa, K Chiba, Y Nakanishi, T Kurokawa, ... Lung Cancer 90 (1), 71-77, 2015 | 43 | 2015 |
| QALY and productivity loss: empirical evidence for “double counting” T Shiroiwa, T Fukuda, S Ikeda, K Shimozuma Value in health 16 (4), 581-587, 2013 | 39 | 2013 |
